Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Survival rates of systemic interventions for psoriasis in the Western Japan Psoriasis Registry: A multicenter retrospective study
Tetsuji Yanase, Noriko Tsuruta, Kazuki Yamaguchi, et al.
The Journal of Dermatology (2023) Vol. 50, Iss. 6, pp. 753-765
Closed Access | Times Cited: 11

Showing 11 citing articles:

Drug Survival of IL-17 and IL-23 Inhibitors for Psoriasis: A Systematic Review and Meta-Analysis
Sarah E. Thomas, Liana Barenbrug, Gerjon Hannink, et al.
Drugs (2024) Vol. 84, Iss. 5, pp. 565-578
Open Access | Times Cited: 14
Systemic therapy for psoriasis and the risk of cutaneous infections
Yuko Higashi, Shinichi Imafuku, Noriko Tsuruta, et al.
The Journal of Dermatology (2024) Vol. 51, Iss. 7, pp. 939-949
Open Access | Times Cited: 4
Drug survival, effectiveness and safety of ixekizumab for moderate‐to‐severe psoriasis up to 5 years
Luca Mastorino, Paolo Dapavo, Lorenza Burzi, et al.
Journal of the European Academy of Dermatology and Venereology (2023) Vol. 38, Iss. 3, pp. 568-575
Open Access | Times Cited: 10
Quality of life of patients with pustular psoriasis is inferior to that of patients with plaque psoriasis in Japan: A multicenter study with questionnaires, the short Form‐36, and other patient‐reported outcomes
Shinichi Imafuku, Atsushi Satoh, Hisatomi Arima, et al.
The Journal of Dermatology (2025)
Closed Access
Deucravacitinib, an Oral, Selective, Allosteric Tyrosine Kinase 2 Inhibitor, in Japanese Patients With Plaque Psoriasis: In‐Depth Analysis of Efficacy and Safety in the Phase 3 POETYK PSO‐4 Trial
Yukari Okubo, Akimichi Morita, Shinichi Imafuku, et al.
The Journal of Dermatology (2025)
Open Access
Safety and effectiveness of guselkumab in Japanese patients with psoriasis: 20‐week interim analysis of a postmarketing surveillance study
Yayoi Tada, Yukako Sugiura, Manami Kamishima, et al.
The Journal of Dermatology (2024) Vol. 51, Iss. 6, pp. 779-790
Open Access | Times Cited: 3
Efficacy, drug survival, safety and metabolic parameters of ixekizumab in patients with moderate-to-severe psoriasis in China: A two-year real-world study
Zheng Zhao, Zhanglei Mu, Yan Zhao, et al.
International Immunopharmacology (2024) Vol. 143, pp. 113474-113474
Closed Access | Times Cited: 3
Real-World Discontinuation and Switching Patterns for Interleukin-Inhibitor Treatments in Patients with Moderate-to-Severe Psoriasis in Japan
Yayoi Tada, Ahmed M. Soliman, Kanako Ishii, et al.
Dermatology and Therapy (2023) Vol. 14, Iss. 1, pp. 99-114
Open Access | Times Cited: 6
Bibliometric analysis on the structure and function of IL17
Wenxia Yan, Jianping Li, Liyun Zhang
Egyptian Rheumatology and Rehabilitation (2024) Vol. 51, Iss. 1
Open Access
Comparison of adalimumab with methotrexate for psoriasis: A meta-analysis of randomized controlled studies
Xiaolin Yang, Yan Liu
Medicine (2024) Vol. 103, Iss. 32, pp. e37216-e37216
Open Access
Safety and effectiveness of secukinumab subcutaneous injection in Japanese patients with psoriasis vulgaris and psoriatic arthritis: A post‐marketing surveillance
Ayako Fujishige, Noriko Seko
The Journal of Dermatology (2024) Vol. 52, Iss. 1, pp. 11-23
Closed Access
Page 1

Scroll to top